UPB News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

UP

Mkt Cap

$150.3M

Volume

1.70M

Next Earnings

November 4th

Loading chart

UP

UPBUpstream Bio, Inc. Common Stock

UPB

Pay with—

Available Balance0.00

UP

Mkt Cap

$184.6M

Volume

1.70M

Next Earnings

November 4th

Chart Financials Earnings News About Insider Filings

Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026Upstream Bio announced positive Phase 2 VALIANT trial results for verekitug, a TSLP receptor antagonist, showing a 56% reduction in annualized asthma exacerbation rate at 100 mg every 12 weeks versus placebo. The company plans to initiate Phase 3 trials in Q1 2027 evaluating a 400 mg quarterly dosing regimen in severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP).GlobeNewswire Inc. · Sep 8, 2026

Chronic Obstructive Pulmonary Disease Clinical Trial Landscape Expands: Over 65 Companies Advancing Next-Generation Therapies | DelveInsightOver 65 pharmaceutical companies are advancing 75+ pipeline COPD drugs, with the treatment landscape evolving beyond traditional bronchodilators toward targeted biologics and anti-inflammatory therapies. Recent clinical trial successes include AstraZeneca's tozorakimab meeting primary endpoints in Phase III trials, and multiple companies progressing novel candidates through various development stages.GlobeNewswire Inc. · Apr 23, 2026

Severe Asthma Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight | DelveInsightThe severe asthma drug development pipeline shows strong momentum with 30+ pharmaceutical companies actively developing 35+ pipeline therapies across various clinical stages. Key players including AstraZeneca, Generate Biomedicines, GSK, and others are advancing promising candidates targeting thymic stromal lymphopoietin inhibitors and interleukin pathways. Recent approvals and positive trial results, including GSK's Exdensur and Upstream Bio's verekitug, demonstrate progress in addressing this unmet medical need.GlobeNewswire Inc. · Apr 7, 2026

From Lungs To Nasal Polyps: Sanofi Finds Success With 2-in-1 Inflammation BlockerSanofi reported positive Phase 2 data for lunsekimig, its bispecific antibody targeting TSLP and IL-13. The drug met primary endpoints in asthma and nasal polyp studies with significant improvements in exacerbations and polyp size. However, an atopic dermatitis trial missed its primary endpoint, though secondary measures showed some clinical activity. The drug demonstrated a favorable safety profile across all studies.Benzinga · Apr 7, 2026

Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual MeetingUpstream Bio announced additional analyses from its Phase 2 VIBRANT trial of verekitug for chronic rhinosinusitis with nasal polyps (CRSwNP). The drug met its primary endpoint with a nasal polyp score reduction of -1.95 (p < 0.0001) and reduced the need for surgery or systemic corticosteroids by 76% compared to placebo. The company plans to initiate Phase 3 trials in CRSwNP and severe asthma following regulatory interactions.GlobeNewswire Inc. · Mar 1, 2026

Upstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026Upstream Bio announced it will present additional efficacy analyses from the Phase 2 VIBRANT trial of verekitug for chronic rhinosinusitis with nasal polyps at the AAAAI Congress 2026. The presentation will include new analyses assessing verekitug's efficacy with adjustment for concomitant rescue therapy use. Verekitug is a novel monoclonal antibody targeting the TSLP receptor and is currently in development for multiple inflammatory diseases including severe asthma and COPD.GlobeNewswire Inc. · Feb 26, 2026

Upstream Bio to Participate in Upcoming March Investor ConferencesUpstream Bio announced that CEO Rand Sutherland will participate in two major investor conferences in March 2026: the TD Cowen 46th Annual Health Care Conference on March 4 and the Leerink Partners Global Healthcare Conference on March 9. The company is developing verekitug, a TSLP receptor antagonist in Phase 2 trials for severe respiratory disorders including chronic rhinosinusitis with nasal polyps, severe asthma, and COPD.GlobeNewswire Inc. · Feb 25, 2026

Upstream Bio to Host Webcast to Report Top-Line Results from the Phase 2 VALIANT Trial of Verekitug in Patients with Severe AsthmaUpstream Bio announced it will report top-line results from the Phase 2 VALIANT trial of verekitug, a TSLP receptor antagonist for severe asthma treatment, on February 11, 2026. The trial evaluated 478 patients across multiple dosing regimens in a randomized, double-blind, placebo-controlled study.GlobeNewswire Inc. · Feb 10, 2026

Upstream Bio to Participate in Upcoming November Investor ConferencesUpstream Bio, a clinical-stage biotechnology company, will participate in multiple investor conferences in November 2025, presenting its research on verekitug, a potential treatment for inflammatory respiratory diseases.GlobeNewswire Inc. · Oct 31, 2025

Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP ReceptorUpstream Bio presented data at the EAACI Congress showing that its novel antibody verekitug, which targets the TSLP receptor, has greater potency compared to treatments targeting the TSLP ligand. This suggests verekitug may have a differentiated profile across inflammatory diseases like severe asthma, COPD, and chronic rhinosinusitis.GlobeNewswire Inc. · Jun 15, 2025

to start trading

UP

UPBUpstream Bio, Inc. Common Stock

UPB

Pay with—

Available Balance0.00

Your PositionYou don't own any UPB yet.

Related Tickers

Earnings